Older adults are at high risk of developing cardiovascular disease (CVD). Pre-clinical studies indicate that resveratrol (RSV), a polyphenol commonly found in grapes and red wine, may help prevent development of CVD. Based on our previous reports where the 300 mg and 1000 mg doses appeared safe and improved psychomotor function in a dose-dependent manner, our hypothesis was that RSV would reduce biomarkers of CVD risk in overweight, but otherwise healthy older adults and that 1000 mg would lower CVD biomarkers >300 mg. This analysis was performed on samples from older participants (65 years and older) who were randomized to a 90 day RSV treatment with 300 mg (n = 10), 1000 mg (n = 9) or placebo (n = 10). We measured levels of CVD risk biomarkers i.e. oxidized low-density lipoprotein (oxLDL), soluble E-selectin-1 (sE-selectin), soluble Intercellular Adhesion Molecule-1 (sICAM-1), Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1), total plasminogen activator inhibitor (tPAI-1). Statistical significance was set at p < 0.05. Both sVCAM-1 and tPAI increased significantly more in the 1000 mg vs. 300 mg and placebo groups. Other biomarkers (300 mg vs. 1000 mg vs. placebo: oxLDL, sEselectin-1 and sICAM-1) followed the same trend toward higher levels in the 1000 mg group compared to the 300 mg and placebo groups, without reaching statistical significance. This pilot project suggests that a higher dose of RSV may increase the levels of CVD risk biomarkers in overweight older adults. Given no change in the CVD risk biomarkers in response to a lower dose, future studies should test the effects of different doses of RSV to evaluate potential detrimental effects of higher doses on CVD biomarkers and measures of cardiovascular function in older adults at risk for CVD.

中文翻译：

---

一项超前研究显示，高剂量白藜芦醇可增加超重老年人的心血管疾病风险生物标志物水平。

老年人患心血管疾病（CVD）的风险很高。临床前研究表明，白藜芦醇（RSV）是葡萄和红酒中常见的一种多酚，可能有助于预防CVD的发展。根据我们以前的报道，其中300 mg和1000 mg剂量表现出安全性并以剂量依赖性方式改善了精神运动功能，我们的假设是RSV可以降低超重的CVD风险的生物标志物，否则健康的老年人，而1000 mg可以较低的CVD生物标志物> 300 mg。这项分析是针对年龄较大的参与者（65岁及65岁以上）的样本进行的，这些样本被随机分为90天RSV治疗，剂量分别为300 mg（n = 10），1000 mg（n = 9）或安慰剂（n = 10）。我们测量了CVD风险生物标志物的水平，即氧化的低密度脂蛋白（oxLDL），可溶性E-选择素1（sE-选择素），可溶性细胞间粘附分子1（sICAM-1），可溶性血管细胞粘附分子1（sVCAM-1），总纤溶酶原激活物抑制剂（tPAI-1）。统计学显着性设定为p <0.05。与300 mg组和安慰剂组相比，1000 mg组sVCAM-1和tPAI均显着增加。与300 mg和安慰剂组相比，其他生物标志物（300 mg vs. 1000 mg vs.安慰剂：oxLDL，sEselectin-1和sICAM-1）遵循相同的趋势，即1000 mg组的水平更高。该试点项目表明，较高剂量的RSV可能会增加超重老年人的CVD危险生物标志物水平。鉴于较低的剂量，CVD风险生物标志物没有变化，